Other OTC - Delayed Quote USD

Agile Therapeutics, Inc. (AGRX)

0.4003 +0.0303 (+8.19%)
At close: April 24 at 3:03 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Alfred F. Altomari Chairman, President & CEO 644.4k -- 1959
Mr. Geoffrey P. Gilmore Senior VP & Chief Administrative Officer 478.92k -- 1966
Dr. Paul Korner M.B.A., M.D. Senior VP & Chief Medical Officer 480.4k -- 1966
Mr. Scott M. Coiante CFO, Senior VP & Treasurer 520.45k -- 1967
Matthew Riley Head of Investor Relations & Corporate Communications -- -- --
Mr. Robert G. Conway M.E. Senior VP and Chief Corporate Planning & Supply Chain Officer 444.11k -- 1958
Ms. Amy Welsh Senior VP & Chief Commercial Officer -- -- 1971

Agile Therapeutics, Inc.

500 College Road East
Suite 310
Princeton, NJ 08540
United States
609 683 1880 https://www.agiletherapeutics.com
Sector: 
Healthcare
Full Time Employees: 
19

Description

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Corporate Governance

Agile Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Agile Therapeutics, Inc. Earnings Call

Related Tickers

BFRI Biofrontera Inc.
1.6600
+10.67%
 
SHPH Shuttle Pharmaceuticals Holdings, Inc.
0.3890
+0.26%
 
GHSI Guardion Health Sciences, Inc.
7.98
-1.12%
 
AYTU Aytu BioPharma, Inc.
2.8000
+2.94%
 
ETON Eton Pharmaceuticals, Inc.
3.2100
-2.13%
 
PTPI Petros Pharmaceuticals, Inc.
0.6344
-6.72%
 
AKAN Akanda Corp.
0.0897
-2.39%
 
YCBD cbdMD, Inc.
0.9000
-1.11%
 
CPHI China Pharma Holdings, Inc.
0.3150
-0.76%
 
FLGC Flora Growth Corp.
1.5500
-10.92%